Sobi Announces CHMP's Positive Opinion For Aspaveli

The European Medicines Agency’s CHMP has issued a positive opinion recommending marketing authorisation for Aspaveli (pegcetacoplan) to treat adult and adolescent patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis, citing positive Phase 3 VALIANT results. A European Commission decision is expected in Q1 2026; Sobi (SOBI.ST) and partner Apellis, which hold global co-development rights for systemic pegcetacoplan, would gain a commercial foothold in a niche complement-mediated kidney-disease market if approval is granted.

Analysis

The European Medicines Agency's CHMP has adopted a positive opinion recommending marketing authorisation for Aspaveli (pegcetacoplan) to treat adult and adolescent patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis, citing positive results from the Phase 3 VALIANT study. This recommendation is a clear regulatory milestone and moves the file to the European Commission, which Sobi says is expected to make a decision in Q1 2026.

Sobi (SOBI.ST) and partner Apellis, which hold global co-development rights for systemic pegcetacoplan, would secure EU commercial rights on approval and gain entry into a narrow complement-mediated kidney-disease niche with concentrated specialist demand. Market signals attached to the report show moderately positive sentiment (score 0.45) and stronger per-ticker sentiment for Apellis (0.6), while a market impact score of 0.35 implies investors view the approval as constructive but not transformational at this stage.

Material near-term risks remain regulatory (final EC approval) and commercial (label scope, pricing and reimbursement, specialist uptake) over the extended timeline to Q1 2026; those factors will determine revenue potential from a limited patient population. Key value-driving catalysts to monitor are the full VALIANT dataset, the formal EC decision, and early payer/health-technology assessment signals that will meaningfully change the investment case.

Key Decisions for Investors

• Consider a modest, tactical long exposure to Apellis (and Sobi for EU-listed exposure) to capture upside from the CHMP positive opinion, but size positions conservatively because the European Commission decision is pending and the market impact appears limited
• Prioritize monitoring the full Phase 3 VALIANT data release, EC approval timing, label details and early reimbursement discussions and use those events to re-assess conviction before materially increasing exposure
• If already exposed, consider hedging regulatory/timing risk with options or trimming positions ahead of the EC decision; if underweight, wait for EC approval or clear payer signals before adding a larger position